



PRESS RELEASE

October 25, 2023

CombiGene AB (publ): Nominating committee

The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting ("AGM") 2023

The AGM 2023 resolved that a nominating committee should be appointed in accordance with the following: "The nominating committee shall consist of representatives for the three largest shareholders in terms of votes as of 30 September each year. If any of these shareholders refrains from appointing a representative, the following shareholders shall, in the order of magnitude, be given the opportunity to appoint a representative until three members have been appointed. The names of the members in the nominating committee must be published by the company no later than six months prior to the coming AGM. The shareholder representative who represents the largest shareholder, shall be appointed chairman of the nominating committee, unless the nominating committee decides otherwise".

The nominating committee has been constituted in accordance with the resolution adopted by the AGM 2023. The nominating committee consists of Kjetil Myrliid Aasen, Ivar Nordqvist and Marcus Isaksson representing Thoren Tillväxt AB.

The nominating committee's tasks include submitting proposals to the AGM regarding:

- Chairman of the AGM
- Election of board members
- Chairman of the board of directors
- Remuneration to the board of directors including the chairman
- Election of auditor and remuneration to the auditor
- Rules of procedure for the nominating committee.

Shareholders may submit proposals to the Nominating Committee no later than eight weeks prior to the 2024 Annual General Meeting. Proposals can be sent by e-mail to shareholders@combigene.com or letter to CombiGene AB, Attn: Nominating Committee, Agavägen 52A, SE-181 55 Lidingö, Sweden.

About CombiGene AB

CombiGene's vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market. The company's Certified Advisor is FNCA Sweden AB.

For more information, please contact:

CombiGene AB (publ)

Peter Ekolind, CEO

Phone: +46 8 35 73 55

peter.ekolind@combigene.com